A targeted oral therapy can slow kidney failure by nearly fifty percent
Innovative oral treatments are transforming the fight against chronic kidney disease by targeting specific immune pathways, potentially reducing the rate of organ failure by nearly fifty percent for patients worldwide.
A breakthrough oral therapy called iptacopan is redefining the treatment of IgA nephropathy by inhibiting a specific protein known as factor B. In clinical trials, this targeted approach slowed the decline of kidney function by an impressive 49.3 percent over a two-year period. Unlike traditional immunosuppressants that can carry high infection risks, this medication intervenes at the root of the disease to prevent inflammation before it damages the kidneys.
There's more to this story — open the app to keep reading.